Stratos Wealth Partners LTD. Purchases 10,346 Shares of AbbVie Inc. $ABBV

Stratos Wealth Partners LTD. lifted its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 6.2% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 178,266 shares of the company’s stock after purchasing an additional 10,346 shares during the period. Stratos Wealth Partners LTD.’s holdings in AbbVie were worth $41,276,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ABBV. Evolution Wealth Management Inc. acquired a new position in shares of AbbVie in the 2nd quarter worth approximately $26,000. Spurstone Advisory Services LLC purchased a new position in shares of AbbVie during the second quarter valued at approximately $28,000. Financial Gravity Companies Inc. bought a new stake in shares of AbbVie in the 2nd quarter worth $36,000. Delos Wealth Advisors LLC bought a new position in AbbVie during the second quarter valued at about $39,000. Finally, Cloud Capital Management LLC purchased a new position in shares of AbbVie in the third quarter worth about $53,000. 70.23% of the stock is owned by institutional investors and hedge funds.

AbbVie Trading Down 0.4%

ABBV opened at $222.32 on Wednesday. The stock has a 50-day moving average price of $223.67 and a 200-day moving average price of $220.29. The stock has a market capitalization of $392.93 billion, a P/E ratio of 94.20, a PEG ratio of 0.78 and a beta of 0.35. AbbVie Inc. has a 12-month low of $164.39 and a 12-month high of $244.81.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. The company had revenue of $16.62 billion during the quarter, compared to analyst estimates of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 4,184.47%. The firm’s revenue was up 10.0% compared to the same quarter last year. During the same period in the prior year, the business posted $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, equities research analysts predict that AbbVie Inc. will post 12.31 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on ABBV. Wall Street Zen downgraded shares of AbbVie from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 3rd. Raymond James Financial set a $256.00 target price on AbbVie in a research report on Monday, November 3rd. BMO Capital Markets restated an “outperform” rating and issued a $258.00 target price on shares of AbbVie in a research note on Thursday, January 15th. UBS Group decreased their price target on AbbVie from $240.00 to $230.00 and set a “neutral” rating on the stock in a research report on Thursday, February 5th. Finally, Sanford C. Bernstein restated a “market perform” rating on shares of AbbVie in a research report on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and nine have given a Hold rating to the company. According to MarketBeat, AbbVie has an average rating of “Moderate Buy” and an average price target of $251.00.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.